MMED MiniMed Group, Inc.
MiniMed Group, Inc. operates as a medical technology company that develops, manufactures, and markets medical equipment for the management of diabetes. The company offers technologies including insulin delivery devices, such as insulin pumps and pens, continuous glucose monitors, other consumables, supplies, and related software and services. It serves people with diabetes who require insulin therapy, which represents all people with T1D and a subset of those with T2D. The company's platform includes Automated Insulin Delivery (AID) systems for glucose sensing and automated insulin dosing and administration for glycemic control and Smart Multiple Daily Injection (MDI) systems for self-administering insulin by manual injections, which include InPen, Simplera Sync, or Guardian 4 sensor, and wraparound applications and services. It also offers CareLink, a software platform that provides support for person with diabetes, their caretakers, and HCPS. MiniMed Group, Inc. was founded in 1983 and is headquartered in Northridge, California.…
Industry Peers
Medical Instruments & SuppliesKey Statistics
About MiniMed Group (NASDAQ: MMED)
›
MiniMed Group (NASDAQ: MMED) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Instruments & Supplies industry, part of the Healthcare sector, and reports about 8,000 employees.
The shares were at 16.26 USD on 19 November 2026. Its 52-week range is 10.65 USD to 24.43 USD: the price is 33.4% below the high and 52.7% above the low.
Its market capitalisation is 4.57B USD.
MiniMed Group reports return on equity of -9.2%, an operating margin of 4.0% and revenue up 16.6% year over year.
It holds more cash than debt, a net cash position of 148.00M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 15 analysts cover the stock, with an average rating of Buy; their mean price target of 25.33 USD is 55.8% above the current price.